MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: Neuroprotective strategies

Journal of Neurology, Supplement

Volumn 247, Issue 2, 2000, Pages 95-102

  Grünblatt, Edna ^a   Mandel, Silvia ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Neurodegeneration; Neuroprotection; Oxidative stress; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; APOMORPHINE; ASCORBIC ACID; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEFEROXAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON CHELATING AGENT; LEVODOPA; LIPOPOLYSACCHARIDE; NEUROPROTECTIVE AGENT; NEUROTOXIN; NEUROTROPIC AGENT; NITRIC OXIDE SYNTHASE INHIBITOR; OXIDOPAMINE; RASAGILINE; SCAVENGER; SELEGILINE; THIOCTIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOPSY; CLINICAL TRIAL; CONFERENCE PAPER; GENE MUTATION; HUMAN; INFLAMMATION; MICROGLIA; MONKEY; MOUSE; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RODENT; SIDE EFFECT; SUBSTANTIA NIGRA;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS;

EID: 0034050672     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (99)

1. Acuna-Castroviejo D, Coto-Montes A, Monti MG, Ortiz GG, Reiter RJ (1997) Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 60:23-29
2. Akiyama H, McGeer PL (1989) Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 489:247-253
3. Aubin N, Curet O, Deffois A, Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopumine depletion in mice. J Neurochem 71: 1635-1642
4. Ben-Shachar D, Eshel G, Finberg JP, Youdim MBH (1991) The iron chelator desferrioxaminc (Desferal) retards 6-hydroxydopamine-induced generation of nigrostriatal dopamine. J Neurochem 56:1441-1444
5. Ben-Shachar D, Eshel G, Riederer P, Youdim MBH (1992) Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann Neurol 32 (suppl):S105-S110
6. Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem 57:2133-2135
7. Biewenga GP, Haenen RG, Bast A (1997) The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 29:315-331
8. Blum-Degen D, Müller T, Kühn W, Gerlach M, Przuntek H, Riederer P. (1995) Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 202:17-20
9. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80:4546-4550
10. Cadet JL, Katz M, Jackson-Lewis V, Fahn S (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476:5-10
11. Chiueh CC, Huang SJ, Murphy DL (1992) Enhanced hydroxyl radical generation by 2'-methyl analog of MPTP: reversal by clorgyline and deprenyl. Synapse 11:346-348
12. +. Free Radic Biol Med 13: 581-583
13. Chiueh CC, Miyake H, Peng MT (1993) Role of dopamine autoxidation. hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 60:251-258
14. Chiueh CC, Rauhala P (1997) Free radicals and MPTP-induced selective destruction of substantia nigra compacta neurons. Adv Pharmacol 42:796-800
15. Cohen G, Heikkila RE (1974) The generation of hydrogen peroxide, superoxide radical and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biochem 249:2447-2452
16. Collart MA, Baeuerle P, Vassalli P (1990) Regulation of tumor necrosis factor-α transcription in macrophages: involvement of four kB-like motifs and of constitutive and inducible forms of NF-kB. Mol Cell Biol 10:1498-1506
17. Davis GC, Williams AC, Markey SP, Ebert MH. Caine ED, Reichert CM, Kopin IJ (1979) Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiat Res 1:249-254
18. Di Monte D, Sandy MS, Smith MT (1987) Increase efflux rather than oxidation is the mechanism of glutathione depletion by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Biophys Res Commun 148: 153-160
19. Finberg JP, Takashima T, Johnston JM, Commissiong JW (1998) Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroprot 9:703-707
20. Gassen M, Glinka Y, Pinchasi B, Youdim MBH (1996) Apomorphine is a highly potent free radical scavenger in rat mitochondrial fraction. Eur J Pharmacol 308:219-225
21. Gassen M, Gross A, Youdim MBH (1998) Apomorphine enantiomers protect pheochromocytoma (PC12) cells from oxidative stress induced by hydrogen peroxide and 6-hydroxydopamine. Mov Disord 13:242-248
22. Gassen M, Youdim MBH (1997) The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol 80:159-166
23. Gerfen CR, Baimbridge KG, Thibault J (1987) The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J Neurosci 7:3935-3944
24. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain iron as a cause of neurodegeneration? J Neurochem 63:793-807
25. Gerlach M, Trautwein AX, Zecca L, Youdim MBH, Riederer P (1995) Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J Neurochem 65:923-926
26. German DC, Manaye KF, Sonsalla PK, Brooks BA (1992) Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann New York Acad Sci 648: 42-62
27. Glinka Y, Gassen M, Youdim MBH (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm (suppl) 50:55-66
28. Glinka Y, Tipton KF, Youdim MBH (1996) Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem 66: 2004-2010
29. Glinka YY, Youdim MBH (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol 292:329-332
30. Gotz ME, Kunig G, Riederer P, Youdim MBH (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63:37-122
31. Goulet M, Morissette M, Calon F, Blanchet PJ, Falardeau P, Bedard PJ, Di Paolo T (1997) Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drugnaive N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis. Neuroscience 79:497-507
32. Grünblatt E, Mandel S, Berkuzki T, Youdim MBH (1999) Apomorphine protects against MPTP induced neurotoxicity in mice. Mov Disord. In press
33. Grünblatt E, Mandel S, Gassen M, Youdim MBH (1999) Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoyicity. J Neural Transm (suppl) 55:57-70
34. Hassouna I, Wickert H, Zimmermann M, Gillardon F (1996) Increase in bax expression in substantia nigra following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment of mice. Neurosci Lett 204:85-88
35. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467-469
36. Hunot S, Brugg B, Richard D, Michel PP, Muriel MP, Ruberg M, Faucheux BA, Agid Y, Hirsch EC (1997) Nuclear translocation of NF-κB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc Natl Acad Sci USA 94:7531-7536
37. Iacopino AM, Christakos S (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 87:4078-4082
38. Iacopino AM, Christakos S, German D, Sonsalla PK, Altar CA (1992) Calbindin-D28k-containing neurons in animal models of neurodegeneration: possible protection from excitotoxicity. Brain Res Mol Brain Res 13:251-261
39. Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect 2:327-340
40. Jenner P (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord (suppl) 13:24-34
41. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology (suppl) 47:161-170
42. Katiyar SK, Matsui MS, Elmets CA, Mukhtar H (1999) Polyphenolic antioxidant (-)epigallocatechin-3-gallate from green tea reduces UVB-induced inflammatory responses and infiltration of leukocytes in human skin. Photochem Photobiol 69:148-153
43. Kostrzewa RM, Jacobowitz DM (1974) Pharmacological action of 6-hydroxydopamine. Pharmacol Rev 26:199-288
44. Kostyuk VA, Potapovich AI (1998) Antiradical and chelating effects in fluvonoid protection against silica-induced cell injury. Arch Biochem Biophys 355:43-48
45. Kotler M, Rodriguez C, Sainz RM, Antolin I, Menendez-Pelaez A (1998) Melatonin increases gene expression for antioxidant enzymes in rat brain cortex. J Pineal Res 24:83-89
46. Kumar R, Agarwal AK, Seth PK (1995) Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 64:1703-1707
47. Lan J, Jiang DH (1997) Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transm 104:649-660
48. Leenders KL, Antonini A, Schwarzbach R, Smith-Jones P, Reist H, Ben-Shachar D, Youdim MBH, Henn V (1994) Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol. J Neural Transm (suppl) 43:123-132
49. Lin M, Rippe RA, Niemela O, Brittenham G, Tsukamoto H (1997) Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Phys 272:G1355-G1364
50. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MBH (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochem Biophys Acta 1316: 160-168
51. Lode HN, Bruchelt G, Rieth AG, Niethammer D (1990) Release of iron from ferritin by 6-hydroxydopamine under anaerobic conditions. Free Radical Res 11:153-158
52. Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teravainen H (1997) Simultaneous MAO-B and COMT inhibition in L-DOPA treated patients with Parkinson's disease. Mov Disord 12: 497-505
53. + toxicity in substantia nigra: protection by desferrioxamine. Brain Res 773:76-81
54. McGeer PL, Itagaki S, McGeer EG (1988) Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol 76: 550-557
55. Mizuno Y, Suzuki K, Sone N, Saitoh T (1988) Inhibition of mitochondrial respiration by MPTP in mouse brain. Neurosci Lett 3:349-353
56. Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, Hattori N, Mizuno Y (1994) Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced hemiparkinsonism in monkeys. Neurosci Lett 168:251-253
57. Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, Riederer P, Nagatsu T (1996) bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett 215:137-139
58. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T (1995) Transforming growth faclor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett 193: 129-132
59. Mogi M, Harada M, Kondo T, Riederer P, Inuguki H, Minami M, Nagatsu T (1994) Interleukin-1β, interleukin-6. epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147-150
60. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth tactor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonian and Parkinson's disease. Neurosci Lett 211:13-16
61. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994) Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208-210
62. Monteiro HP, Winterbourn CC (1989) 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 38:4177-4182
63. Muralikrishnan D, Mohanakumar KP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12:905-912
64. Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T (1996) Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 46:791-795
65. Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660:8-18
66. Ogawa N, Asanuma M, Kondo Y, Hirata H, Nishibayashi S, Mori A (1994) Changes in lipid peroxidation, Cu/Zn-superoxide dismutase and its mRNA following an intracerebroventricular injection of 6-hydroxydopamine in mice. Brain Res 646: 337-340
67. Olanow CW, Youdim MBH (1996) Iron and neurodegeneration: prospects for neuroprotection. In: Olanow CW, Jenner P, Youdim MBH (eds) Neurodegeneration and neuroprotection in Parkinson's disease. London Academic Press, pp 55-69
68. Pearce RK, Owen A, Daniel S, Jenner P, Marsden CD (1997) Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm 104:661-677
69. Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL (1992) Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29:699-671
70. Perumal AS, Tordzro WK, Katz M, Jackson-Lewis V, Cooper TB, Fahn S, Cadet JL (1989) Regional effects of 6-hydroxydopamine on free radical scavengers in rat brain. Brain Res 504: 139-141
71. Pietta P, Simonetti P, Gardana C, Brusamolino A, Vlorazzoni P, Bombardelli E (1998) Relationship between rate and extent of catechin absorption and plasma antioxidant status. Biochem Mol Biol Inter 46:895-903
72. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL, Dowson TM (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopuminergic neurotoxicity. Proc Natl Acad Sci USA 93 4565-4571
73. Randall BL (1992) Iron, aging, and human disease: historical background and new hypotheses. In: Randall BL (ed) Iron and human disease. CRC Press, pp 1-23
74. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515-520
75. Rosler M, Retz W, Thome J, Riederer P (1998) Free radicals in Alzheimer's dementia: currently available therapeutic strategies. J Neural Transm Suppl 54:211-219
76. + toxicity on striatal dopaminergic terminals. J Neurochem 68:732-738
77. Schreck R, Meier B, Männel DN, Droge W, Baeuerle PA (1992) Dithiocarbamates as potent inhibitors of nuclear factor kB activation in intact cells. J Exp Med 175:1181-1194
78. Schreck R, Rieber P, Baeuerle PA (1991) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV-1. EMBO J 10:2247-2258
79. Schulz JB, Matthews RT, Beal MF (1995) Role of nitric oxide in neurodegenerative diseases. Curr Opin Neurol 8:480-486
80. Seaton TA, Cooper JM, Schapira AHV (1997) Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res 777:110-118
81. Sengstock GJ, Olanow CW, Dunn AJ, Barone S Jr, Arendash GW (1994) Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp Neurol 130:82-94
82. Shimizu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto KI (1990) Involvement of a NF-kB like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol 10:561-568
83. Singer TP, Castagnoli N Jr, Ramsay RR, Treor AJ (1987) Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 49:1-8
84. Soghomonian JJ, Laprade N (1997) Glutamate decarboxylase (GAD67 and GAD65) gene expression is increased in a subpopulation of neurons in the putamen of Parkinsonian monkeys. Synapse 27:122-132
85. Suzuki YT, Packer L (1993) Inhibition of NF-kB activation by vitamin E derivatives. Biochem Biophys Res Commun 193:277-283
86. Takao T, Culp SG, De Souza EB (1993) Reciprocal modulation of interleukin-1β (IL-1β) and IL-1 receptors by lipopolysaccharide (endotoxin) treatment in the mouse brain-endocrine-immune axis. Endocrinology 132:1497-1504
87. Tang TP, Ma YL, Chao CC, Chen KY, Lee EH (1998) Enhanced glial cell line-derived neurotrophic factor mRNA expression upon deprenyl and melatonin treatment. J Neurosci Res 53:593-604
88. Tatton WG (1993) Selegiline can mediate neuronal rescue rather than neuronal protection. Mov Disord 8: S20-S30
89. Tatton WG, Chalmers-Redman RM, Ju WY, Wadia J, Tatton NA (1997) Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm Suppl 49:245-268
90. Temlett JA, Landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe element microanalysis. J Neurochem 62:134-146
91. Tohgi H, Abe T, Saheki M, Hamato F, Sasaki K, Takahashi S (1995) Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment. Neurosci Lett 184:21-24
92. Vatassery GT (1998) Vitamin E and other endogenous antioxidants in the central nervous system. Geriatrics 1: 25-27
93. Yamaguchi T, Kuraishi Y, Minami M, Nakai S, Hirai Y, Satoh M (1991) Methamphetamine-induced expression of interleukin-1 beta mRNA in the rat hypothalamus. Neurosci Lett 128:90-92
94. Ye FQ, Allen PS, Martin WR (1996) Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. Mov Disord 11:243-249
95. Youdim MBH, Ben-Shachar D, Eshel G, Finberg JP, Riederer P (1993) The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. Adv Neurol 60:259-266
96. Youdim MBH, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 8:1-12
97. Youdim MBH, Krishna G, Chiueh CC (1999) Neuroprotective strategies in Parkinson's disease and Huntington's chorea: MPTP and 3-NP induced neurodegeneration as models. In: Sandberg PR, Nishino H, Borlongan CV (eds) Mitochondrial inhibition and neurodegenerative disorders. Humano Press NY. In press
98. Youdim MBH, Riederer P (1997) Understanding Parkinson's disease. Sci Am 276:52-59
99. Zecca L, Mecacci C, Seraglia R, Parati E (1992) The chemical characterization of melanin contained in substantia nigra of human brain. Biochem Biophys Acta 1138:6-10